| 1. |
- Hellgren, A, et al.
(författare)
-
Health-related quality of life after liver transplantation.
- 1998
-
Ingår i: Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. - 1074-3022. ; 4:3, s. 215-21
-
Tidskriftsartikel (refereegranskat)abstract
- To gather information regarding how to best assist liver transplant recipients in improving their self-care capacity and well-being, we investigated their total health situation. A retrospective, cross-sectional survey with up to a 10-year follow-up concerning experienced health and quality of life after liver transplantation (LTX) was conducted. The aim of this study was to provide descriptive data on the experienced health and health-related quality of life (HRQOL) after LTX and to evaluate whether the pretransplantation medical conditions affected these parameters. All patients who had undergone LTX, were alive at the time of the study, and had a follow-up of more than 6 months (n = 134) were asked to complete three self-administered questionnaires. The response rate was 95% (n = 120). There was no correlation between pretransplantation Child-Pugh score and HRQOL after LTX. Liver transplant recipients were more limited in their physical health than healthy subjects but were equal in social functioning and mental health. Twenty-six percent suffered from severe bodily pain. A significant difference was reported in all health areas, with the exception of vitality and social functioning, between employed and unemployed transplant recipients. Liver transplant recipients suffered from limited physical functioning many years after transplantation. Their social functioning and mental health were not negatively affected. This study emphasizes that bodily pain and difficulties in performing regular activities because of physical illness are problems frequently experienced by liver transplant recipients.
|
|
| 2. |
- Biver, N, et al.
(författare)
-
Long-term evolution of the outgassing of comet Hale-Bopp from radio observations
- 1997
-
Ingår i: EARTH MOON AND PLANETS. - : KLUWER ACADEMIC PUBL. - 0167-9295. ; 78:1-3, s. 5-11
-
Tidskriftsartikel (refereegranskat)abstract
- C/1995 O1 (Hale-Bopp) has been observed on a regular basis since August 1995 at millimetre and submillimetre wavelengths using IRAM, JCMT, CSO and SEST radio telescopes. The production rates of eight molecular species (CO, HCN, CH3OH, H2CO, H2S, CS, CH3CN
|
|
| 3. |
- Freiburghaus, Christian, et al.
(författare)
-
Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995
- 1998
-
Ingår i: Haemophilia. - : Wiley. - 1351-8216 .- 1365-2516. ; 4:1, s. 16-20
-
Tidskriftsartikel (refereegranskat)abstract
- Treatment of severe bleeding and the performance of surgery in haemophilia patients with inhibitors creates severe problems. It is generally agreed that treatment is most effective if circulating levels of factor VIII/IX can be achieved long enough for control of haemostasis. Immunoadsorption with protein A for the removal of inhibitor has improved treatment for patients with initial inhibitor titres too high to neutralize by infusion alone. This is a summary of our experience in Malmo regarding immunoadsorption and haemostasis. A total of 19 applications with immunoadsorption in 10 patients were performed. On all occasions it was possible to eliminate totally the inhibitor or reduce it to low levels that could easily be neutralized with factor concentrate. Haemostatic levels of coagulation factors could be maintained for 5-9 days in all but one patient. This period was sufficient to stop ongoing haemorrhage or prevent excessive bleeding at surgical interventions.
|
|
| 4. |
- Freiburghaus, Christian, et al.
(författare)
-
Tolerance induction using the Malmo treatment model 1982-1995
- 1999
-
Ingår i: Haemophilia. - : Wiley. - 1351-8216. ; 5:1, s. 32-39
-
Tidskriftsartikel (refereegranskat)abstract
- The ultimate goal in the treatment of haemophilia patients with inhibitors is to eradicate permanently the inhibitor and induce tolerance. Here we summarize our experience at the Malmo centre regarding tolerance induction according to the Malmo Treatment Model. The protocol includes immunoadsorption if needed, neutralization of inhibitor and replacement with factor concentrates, cyclophosphamide intravenously for 2 days (12-15 mg kg-1 bw) and then orally (2-3 mg kg-1 bw) for an additional 8-10 days and intravenous gammaglobulin daily at dosages of 0.4 g kg-1 bw for 5 days. This protocol has been applied in 23 haemophilia patients with inhibitors, 16 haemophilia A patients and seven haemophilia B patients. Altogether 36 attempts have been made to induce tolerance. Ten of the 16 haemophilia A (62.5%) and 6/7 patients with haemophilia B (86%) became tolerant after the treatment. The chances of success or failure are roughly equal, if the series is considered in a historical perspective. The data showed that the chances of success in tolerance induction with the Malmo protocol were best in those patients with low inhibitor titres, with relatively low historical inhibitory peak and with a long interval since the previous replacement therapy. This was especially true where no inflammatory state was present at the start or during tolerance induction. The advantage with this method compared to the high-dose regimen is that in the successful cases tolerance can be achieved within 3-4 weeks.
|
|
| 5. |
- Gunnarsson, I, et al.
(författare)
-
Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus.
- 1997
-
Ingår i: British Journal of Rheumatology. - : Oxford University Press (OUP). - 0263-7103 .- 1460-2172. ; 36, s. 32-
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this study was to compare ongoing production of anti-C1q antibodies (anti-C1q) in peripheral blood with serum anti-C1q levels in patients with systemic lupus erythematosus (SLE), especially in patients with nephritis. Using the ELISPOT technique for the detection of IgG and IgA anti-C1q production, 21 patients with active SLE were investigated. ELISAs for IgG and IgA anti-C1q were compared with the ELISPOT results. Six of the patients were found to have proliferative nephritis (WHO grade III/IV) confirmed by renal biopsy. High numbers of IgG anti-C1q spot-forming cells (SFC), defined as > 20/10(5) plated peripheral blood mononuclear cells (PBMC), were exclusively observed in patients with proliferative nephritis (P < 0.0001). Serum levels of IgG anti-C1q were significantly increased in patients with proliferative nephritis (P = 0.039). High ongoing IgG anti-C1q production was observed in all patients with proliferative nephritis, which may be a contributory factor in the pathogenesis of this disorder. The detection of IgG anti-C1q production may be valuable in the clinical investigation of patients with suspected SLE nephritis.
|
|
| 6. |
|
|
| 7. |
- Gunnarsson, I, et al.
(författare)
-
Mesalazine-induced lupus syndrome
- 1999
-
Ingår i: Lupus. - : SAGE Publications. - 0961-2033 .- 1477-0962. ; 8:6, s. 486-488
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
- Gunnarsson, I, et al.
(författare)
-
Olsalazine-induced lupus syndrome
- 1997
-
Ingår i: Scandinavian journal of rheumatology. - : Informa UK Limited. - 0300-9742 .- 1502-7732. ; 26:1, s. 65-66
-
Tidskriftsartikel (refereegranskat)
|
|
| 9. |
|
|
| 10. |
|
|
